drugset / Trial / NCT00094380
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Phase 1/2
Completed
6 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network (ITN) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the safety of a single dose of RG2077 in patients with systemic lupus erythematosus (SLE) who are currently receiving cyclophosphamide. This study will also determine if RG2077 is effective in decreasing disease activity in these patients. Study hypothesis: CTLA4-Ig mediates a T cell costimulatory blockade that effectively induces an antigen-specific nonresponsiveness in T cells.
Timeline
- Start
- 2004-09
- Primary completion
- 2006-01
- Completion
- 2006-01
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | 0.2 mg/kg | Intravenous |
| Subject | Abatacept | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Abatacept | Other / unclassified | 10 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |